These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25986914)

  • 1. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.
    Zhao SG; Jackson WC; Kothari V; Schipper MJ; Erho N; Evans JR; Speers C; Hamstra DA; Niknafs YS; Nguyen PL; Schaeffer EM; Ross AE; Den RB; Klein EA; Jenkins RB; Davicioni E; Feng FY
    Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):229-36. PubMed ID: 25986914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
    Prensner JR; Zhao S; Erho N; Schipper M; Iyer MK; Dhanasekaran SM; Magi-Galluzzi C; Mehra R; Sahu A; Siddiqui J; Davicioni E; Den RB; Dicker AP; Karnes RJ; Wei JT; Klein EA; Jenkins RB; Chinnaiyan AM; Feng FY
    Lancet Oncol; 2014 Dec; 15(13):1469-1480. PubMed ID: 25456366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer.
    Alshalalfa M; Schliekelman M; Shin H; Erho N; Davicioni E
    Biol Cell; 2015 Jul; 107(7):232-44. PubMed ID: 25900404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer.
    Zhao SG; Evans JR; Kothari V; Sun G; Larm A; Mondine V; Schaeffer EM; Ross AE; Klein EA; Den RB; Dicker AP; Karnes RJ; Erho N; Nguyen PL; Davicioni E; Feng FY
    Clin Cancer Res; 2016 Apr; 22(7):1777-86. PubMed ID: 26631616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.
    Gerke JS; Orth MF; Tolkach Y; Romero-Pérez L; Wehweck FS; Stein S; Musa J; Knott MML; Hölting TLB; Li J; Sannino G; Marchetto A; Ohmura S; Cidre-Aranaz F; Müller-Nurasyid M; Strauch K; Stief C; Kristiansen G; Kirchner T; Buchner A; Grünewald TGP
    Int J Cancer; 2020 Apr; 146(7):2036-2046. PubMed ID: 31732966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer.
    Zhang Y; Yuan Y; Liang P; Zhang Z; Guo X; Xia L; Zhao Y; Shu XS; Sun S; Ying Y; Cheng Y
    Oncotarget; 2017 Jul; 8(28):45459-45469. PubMed ID: 28525372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer.
    Rubicz R; Zhao S; Wright JL; Coleman I; Grasso C; Geybels MS; Leonardson A; Kolb S; April C; Bibikova M; Troyer D; Lance R; Lin DW; Ostrander EA; Nelson PS; Fan JB; Feng Z; Stanford JL
    Mol Oncol; 2017 Feb; 11(2):140-150. PubMed ID: 28145099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review.
    Chen Q; Zhong T
    Drug Des Devel Ther; 2015; 9():5115-22. PubMed ID: 26379424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.
    Rajan P; Stockley J; Sudbery IM; Fleming JT; Hedley A; Kalna G; Sims D; Ponting CP; Heger A; Robson CN; McMenemin RM; Pedley ID; Leung HY
    BMC Cancer; 2014 Dec; 14():977. PubMed ID: 25519703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting POH1 inhibits prostate cancer cell growth and enhances the suppressive efficacy of androgen deprivation and docetaxel.
    Yu W; Li J; Wang Q; Wang B; Zhang L; Liu Y; Tang M; Xu G; Yang Z; Wang X; Zhang J; Liu Y; Shi G
    Prostate; 2019 Aug; 79(11):1304-1315. PubMed ID: 31212367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer.
    Shukla S; Zhang X; Niknafs YS; Xiao L; Mehra R; Cieślik M; Ross A; Schaeffer E; Malik B; Guo S; Freier SM; Bui HH; Siddiqui J; Jing X; Cao X; Dhanasekaran SM; Feng FY; Chinnaiyan AM; Malik R
    Neoplasia; 2016 Aug; 18(8):489-99. PubMed ID: 27566105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
    Zhang L; Guo F; Gao X; Wu Y
    Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
    Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
    Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma proteasomal chymotrypsin-like activity correlates with prostate cancer progression.
    Deng X; Zhou P; Wei X; Uhlman M; Lin Y; Lin X; Wu S; Diao P; Xie H; Liu J; Xie K; Tang P
    Tumour Biol; 2015 Jun; 36(6):4115-21. PubMed ID: 25578495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSMA5 promotes the tumorigenic process of prostate cancer and is related to bortezomib resistance.
    Fu Z; Lu C; Zhang C; Qiao B
    Anticancer Drugs; 2019 Aug; 30(7):e0773. PubMed ID: 30807553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer.
    Barquilha CN; Santos NJ; Monção CCD; Barbosa IC; Lima FO; Justulin LA; Pértega-Gomes N; Felisbino SL
    Oxid Med Cell Longev; 2020; 2020():2148562. PubMed ID: 32411320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.